Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets
Launched by VIATRIS KOREA · Nov 19, 2019
Trial Information
Current as of September 15, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • \[Inclusion criteria\]
- To be eligible to enter this study, the subject will have to meet the following inclusion criteria:
- • 1. Korean patients who have been administered Lyrica CR for the first time according to the current local labeling (indication, dosage and administration).
- • 2. Subjects who have consented to participate in this study by signing the data privacy statement.
- • \[Exclusion criteria\]
- Patients meeting any of the following criteria will not be included in the study:
- • 1. Patients who have deviated from local labeling (indication, dosage and administration) in taking this drug
- • 2. Renal impairment patients with CLCr less than 30 mL/min or who are undergoing hemodialysis.
- • 3. Patients who have hypersensitivity to the active substance (pregabalin) or to any of the excipients.
- • 4. Other patients who are decided to be not prescribed by the investigator under the routine medical practice, considering the balance the overall risk and benefit, for example, patients have suicidal behavior and ideation, or have any risk of these, and/or patients who are in pregnancy or lactation, etc.
About Viatris Korea
Viatris Korea is a leading healthcare company dedicated to providing access to high-quality medicines and enhancing patient care through innovative solutions. As a subsidiary of Viatris, formed from the merger of Mylan and Upjohn, Viatris Korea leverages a robust portfolio of generics, specialty pharmaceuticals, and over-the-counter products to address diverse health needs. Committed to advancing medical research and clinical trials, Viatris Korea collaborates with healthcare professionals and organizations to improve treatment outcomes and contribute to the overall well-being of patients in Korea and beyond. With a strong emphasis on quality, safety, and efficacy, Viatris Korea is at the forefront of transforming healthcare access and delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jeonju, Korea, Republic Of
Jeonju, Jeollabuk Do, Korea, Republic Of
Changwon, Korea, Republic Of
Seoul, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials